Li, Juan <br/><br/>
The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.  [electronic resource] 

 -  Cancer letters  Sep 2013 
 - 237-47 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2013.05.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--immunology<br/>Antineoplastic Agents, Alkylating--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Atrophy<br/>B7-2 Antigen--metabolism<br/>Cyclophosphamide--pharmacology<br/>Drug Synergism<br/>Histocompatibility Antigens Class I--metabolism<br/>Hydrocortisone--pharmacology<br/>Immunologic Factors--metabolism<br/>Immunosuppressive Agents--pharmacology<br/>Interferon-gamma--blood<br/>Male<br/>Melanoma, Experimental--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Inbred C57BL<br/>Protein Binding<br/>Skin Neoplasms--drug therapy<br/>Surface Plasmon Resonance<br/>Thymalfasin<br/>Thymocytes--drug effects<br/>Thymopentin--immunology<br/>Thymosin--analogs & derivatives<br/>Thymus Gland--drug effects<br/>Time Factors<br/>Toll-Like Receptor 2--metabolism<br/>Tumor Burden--drug effects